

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of P. Isakson et al.  
Serial No. TBA  
Filed HEREWITH  
Confirmation No. TBA

Art Unit TBA

For TREATMENT OF INFLAMMATION AND INFLAMMATION-RELATED DISORDERS  
WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITORS AND A  
LEUKOTRIENE B4 RECEPTOR ANTAGONIST  
Examiner TBA

January 3, 2002

PRELIMINARY AMENDMENT A

Prior to calculating the filing fee in this matter, please  
enter the following amendments in the above-referenced  
application.

IN THE RELATED CASE:

Please replace the paragraph on Page 1, lines 7-8 with the  
following:

--This is a continuation of US Application Serial No. 08/661,641,  
filed June 11, 1996 which application is a continuation-in-part  
of US Application Serial No. 08/489,415, filed June 12, 1995.--

IN THE SPECIFICATION:

Please replace the paragraph on page 5, lines 6-12 with the  
following:

--In addition, the invention describes a combination comprising a  
therapeutically-effective amount of a leukotriene B<sub>4</sub> receptor  
antagonist and a cyclooxygenase-2 inhibitor selected from Taisho  
NS-398 (Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]),  
meloxicam (2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-  
methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide), flosulide  
(Methanesulfonamide, N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-  
oxo-1H-inden-5-yl]), Merck MK-966 (2(5H)-Furanone, 4-[4-